Research and Markets: Hospital Insight Series: MRSA Infections (Europe)

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zjs636/hospital_insight_s) has announced the addition of Decision Resources, Inc's new report "Hospital Insight Series: MRSA Infections (Europe)" to their offering.

Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important pathogen that causes serious infections, including skin and skin structure infections, bloodstream infections, lower respiratory tract infections, and bone and joint infections. Drug resistance in MRSA and MRSA's decreased susceptibility to IV vancomycin, the mainstay drug for the treatment of MRSA, poses significant challenges in the treatment of MRSA infections, yet provides opportunities for the uptake of other and emerging MRSA therapies in the European MRSA market.

Hospital Insight Series is a syndicated report series that analyzes the hospital antibiotic prescribing patterns for the treatment of key infections and infections caused by emerging and clinically-important pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA). This report provides insight and analysis of the MRSA infection market in Europe, focusing on the key therapies for the management of MRSA infections in the hospital.

Through audit data from AMR's Hospital Antibiotic Market Guide and primary research with infectious diseases specialists, we are able to understand dynamics of product usage, physicians' treatment patterns, factors that influence prescribing patterns, and reactions to and perceptions of emerging and novel therapies.

Key Topics Covered:

- Executive Summary and Key Findings

- Introduction

- Methodology

- MRSA Patient Population Analysis

- Indication Analysis

- Prescriber Analysis

- Physician Insight and Treatment Analysis

- Product Analysis

- Novel and Emerging Therapies

For more information visit http://www.researchandmarkets.com/research/zjs636/hospital_insight_s

Source: Decision Resources, Inc